U.S. markets closed
  • S&P Futures

    4,172.50
    -3.25 (-0.08%)
     
  • Dow Futures

    34,190.00
    -16.00 (-0.05%)
     
  • Nasdaq Futures

    12,768.00
    -8.75 (-0.07%)
     
  • Russell 2000 Futures

    1,976.40
    -2.90 (-0.15%)
     
  • Crude Oil

    77.33
    +0.19 (+0.25%)
     
  • Gold

    1,875.30
    +3.60 (+0.19%)
     
  • Silver

    22.32
    +0.14 (+0.64%)
     
  • EUR/USD

    1.0737
    +0.0006 (+0.05%)
     
  • 10-Yr Bond

    3.6740
    +0.0400 (+1.10%)
     
  • Vix

    18.66
    -0.77 (-3.96%)
     
  • GBP/USD

    1.2047
    -0.0005 (-0.04%)
     
  • USD/JPY

    131.1580
    +0.0860 (+0.07%)
     
  • BTC-USD

    23,252.08
    +374.56 (+1.64%)
     
  • CMC Crypto 200

    536.91
    +10.95 (+2.08%)
     
  • FTSE 100

    7,864.71
    +28.00 (+0.36%)
     
  • Nikkei 225

    27,543.39
    -142.08 (-0.51%)
     

Company News for Nov 2, 2022

  • Shares of Abiomed, Inc. ABMD surged 49.9% after the company reported third-quarter 2022 earnings of $1.30 per share, beating the Zacks Consensus Estimate of $1.05 per share.

  • ArcBest Corporation’s ARCB shares gained 1% after the company reported third-quarter 2022 earnings of $3.80 per share, surpassing the Zacks Consensus Estimate of $3.75 per share.

  • Shares of Marathon Petroleum Corporation MPC jumped 4.9% after the company reported third-quarter 2022 earnings of $7.81 per share, surpassing the Zacks Consensus Estimate of $6.80 per share.

  • Molson Coors Beverage Company’s TAP shares declined 3.2% after the company reported third-quarter 2022 earnings of $1.32 per share, missing the Zacks Consensus Estimate of $1.36 per share.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
ABIOMED, Inc. (ABMD) : Free Stock Analysis Report
 
Molson Coors Beverage Company (TAP) : Free Stock Analysis Report
 
Marathon Petroleum Corporation (MPC) : Free Stock Analysis Report
 
ArcBest Corporation (ARCB) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research